Go Pro
→ Do this before December or regret it (From Porter & Company) (Ad)tc pixel Free ATOS Stock Alerts

Atossa Genetics (ATOS) Financials

Atossa Genetics logo
$2.39 -0.05 (-2.05%)
Closing price 04:00 PM Eastern
Extended Trading
$2.42 +0.03 (+1.46%)
As of 07:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Atossa Genetics

Annual Income Statements for Atossa Genetics

This table shows Atossa Genetics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -16 -6.37 -11 -23 -17 -22 -21 -27 -30 -26 -35
Consolidated Net Income / (Loss)		 -16 -6.37 -8.12 -11 -17 -18 -21 -27 -30 -26 -35
Net Income / (Loss) Continuing Operations		 -13 -6.37 -8.12 -11 -17 -18 -21 -27 -30 -26 -35
Total Pre-Tax Income 		-13 -6.37 -8.12 -11 -17 -18 -21 -27 -30 -26 -35
Total Operating Income		 -13 -7.97 -7.65 -11 -17 -15 -21 -28 -31 -28 -37
Total Gross Profit		 -0.13 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.13 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 13 7.97 7.65 11 17 15 21 28 31 28 37
Selling, General & Admin Expense		 10 6.48 4.86 7.22 11 8.00 11 13 14 14 16
Research & Development Expense		 2.36 0.77 2.33 4.21 6.65 6.61 9.21 15 17 14 21
Total Other Income / (Expense), net		 0.00 1.60 -0.47 0.03 0.03 -3.22 -0.09 0.73 1.28 2.12 2.37
Interest & Investment Income		 - - - - - - 0.01 0.88 4.34 2.34 2.38
Other Income / (Expense), net		 0.00 1.60 -0.47 0.03 0.03 -3.22 -0.09 -0.15 -3.06 -0.22 -0.01
Income Tax Expense		 0.00 - 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Basic Earnings per Share		 ($8.31) ($2.16) ($10.97) ($5.50) ($2.03) ($1.97) ($0.18) ($0.21) ($0.24) ($3.04) ($4.04)
Weighted Average Basic Shares Outstanding		 1.90M 2.95M 974.77K 4.16M 8.50M 11.31M 116.95M 126.62M 126.08M 8.39M 8.61M
Diluted Earnings per Share		 ($8.31) ($2.16) ($10.97) ($5.50) ($2.03) ($1.97) - ($0.21) ($0.24) ($3.04) ($4.04)
Weighted Average Diluted Shares Outstanding		 1.90M 2.95M 974.77K 4.16M 8.50M 11.31M 116.95M 126.62M 126.08M 8.39M 8.61M
Weighted Average Basic & Diluted Shares Outstanding		 1.90M 2.95M 974.77K 4.16M 8.50M 11.31M 116.95M 126.62M 125.30M 129.17M 8.61M

Quarterly Income Statements for Atossa Genetics

This table shows Atossa Genetics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -6.23 -7.75 -5.88 -6.05 -7.23 -6.35 -6.72 -8.42 -8.69 -11 -9.59
Consolidated Net Income / (Loss)		 -6.23 -7.75 -5.88 -6.05 -7.23 -6.35 -6.72 -8.42 -8.69 -11 -9.59
Net Income / (Loss) Continuing Operations		 -6.23 -7.75 -5.88 -6.05 -7.23 -6.35 -6.72 -8.42 -8.69 -11 -9.59
Total Pre-Tax Income 		-6.23 -7.75 -5.88 -6.05 -7.23 -6.35 -6.72 -8.42 -8.69 -11 -9.59
Total Operating Income		 -7.47 -9.02 -6.98 -7.11 -6.39 -7.15 -7.41 -9.04 -9.25 -11 -9.87
Total Gross Profit		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 7.47 9.02 6.98 7.11 6.39 7.15 7.41 9.04 9.25 11 9.87
Selling, General & Admin Expense		 3.00 3.36 3.23 3.55 2.97 3.75 3.26 3.54 3.88 5.28 5.09
Research & Development Expense		 4.47 5.65 3.75 3.55 3.41 3.40 4.16 5.50 5.37 6.16 4.78
Total Other Income / (Expense), net		 1.24 1.26 1.10 1.06 -0.85 0.80 0.70 0.62 0.56 0.50 0.28
Interest & Investment Income		 1.27 4.23 1.14 1.07 -0.71 -0.87 0.72 0.65 0.57 0.44 0.31
Other Income / (Expense), net		 -0.04 -2.96 -0.04 -0.02 -0.14 1.68 -0.02 -0.03 -0.01 0.06 -0.03
Income Tax Expense		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Basic Earnings per Share		 ($0.05) ($0.06) ($0.05) ($0.05) ($0.06) ($0.04) ($0.78) ($0.07) ($0.07) ($1.27) ($1.11)
Weighted Average Basic Shares Outstanding		 125.79M 126.08M 125.32M 125.73M 125.77M 125.86M 8.62M 129.17M 129.17M 8.61M 8.62M
Diluted Earnings per Share		 ($0.05) ($0.06) ($0.05) ($0.05) ($0.06) ($0.04) ($0.78) ($0.07) ($0.07) ($1.27) ($1.11)
Weighted Average Diluted Shares Outstanding		 125.79M 126.08M 125.32M 125.73M 125.77M 125.86M 8.62M 129.17M 129.17M 8.61M 8.62M
Weighted Average Basic & Diluted Shares Outstanding		 125.30M 125.30M 125.76M 125.76M 125.80M 129.17M 129.17M 129.17M 129.17M 8.61M 8.61M

Annual Cash Flow Statements for Atossa Genetics

This table details how cash moves in and out of Atossa Genetics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -4.78 -0.69 4.19 3.22 2.20 27 97 -25 -22 -17 -30
Net Cash From Operating Activities		 -14 -5.37 -6.59 -8.96 -9.13 -12 -16 -21 -21 -21 -30
Net Cash From Continuing Operating Activities		 -11 -5.37 -6.59 -8.96 -9.13 -12 -16 -21 -21 -21 -30
Net Income / (Loss) Continuing Operations		 -13 -6.37 -8.12 -11 -17 -18 -21 -27 -30 -26 -35
Consolidated Net Income / (Loss)		 -16 -6.37 -8.12 -11 -17 -18 -21 -27 -30 -26 -35
Depreciation Expense		 0.27 0.30 0.13 0.04 0.05 0.05 0.02 0.01 0.02 0.02 0.02
Non-Cash Adjustments To Reconcile Net Income		 0.54 1.98 1.38 2.30 8.63 6.32 5.27 7.12 7.61 4.01 2.65
Changes in Operating Assets and Liabilities, net		 0.63 -1.29 0.02 0.10 -0.57 -0.11 -1.16 -0.93 1.52 0.45 2.35
Net Cash From Investing Activities		 -0.29 -0.01 0.00 -0.11 -0.01 -0.01 -0.01 -4.73 -0.01 -0.02 -0.02
Net Cash From Continuing Investing Activities		 -0.13 -0.01 0.00 -0.11 -0.01 -0.01 -0.01 -4.73 -0.01 -0.02 -0.02
Purchase of Property, Plant & Equipment		 -0.13 -0.01 0.00 -0.11 -0.01 -0.01 -0.01 -0.03 -0.01 -0.02 -0.02
Purchase of Investments		 - - - - - - 0.00 -4.70 0.00 0.00 0.00
Net Cash From Financing Activities		 9.46 4.70 11 12 11 39 113 0.00 -1.48 3.67 0.00
Net Cash From Continuing Financing Activities		 9.46 4.70 11 12 11 39 113 0.00 -1.48 3.67 0.00
Other Financing Activities, net		 - - 0.75 0.00 11 -0.01 44 - 0.00 3.67 0.00

Quarterly Cash Flow Statements for Atossa Genetics

This table details how cash moves in and out of Atossa Genetics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -5.36 -5.57 -4.50 -4.43 -4.76 -3.68 -5.97 -7.26 -6.01 -11 -9.58
Net Cash From Operating Activities		 -3.88 -5.57 -4.70 -4.53 -4.75 -7.05 -5.96 -7.26 -6.01 -11 -9.58
Net Cash From Continuing Operating Activities		 -3.88 -5.57 -4.70 -4.53 -4.75 -7.05 -5.96 -7.26 -6.01 -11 -9.58
Net Income / (Loss) Continuing Operations		 -6.23 -7.75 -5.88 -6.05 -7.23 -6.35 -6.72 -8.42 -8.69 -11 -9.59
Consolidated Net Income / (Loss)		 -6.23 -7.75 -5.88 -6.05 -7.23 -6.35 -6.72 -8.42 -8.69 -11 -9.59
Depreciation Expense		 0.00 0.01 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Non-Cash Adjustments To Reconcile Net Income		 0.93 0.52 0.42 0.35 2.46 0.78 0.56 0.80 0.78 0.50 0.72
Changes in Operating Assets and Liabilities, net		 1.42 1.65 0.76 1.16 0.02 -1.49 0.19 0.36 1.90 -0.11 -0.72
Net Cash From Investing Activities		 -0.00 - -0.01 -0.00 -0.01 - -0.01 - -0.01 -0.01 0.00
Net Cash From Continuing Investing Activities		 -0.00 - -0.01 -0.00 -0.01 - -0.01 - -0.01 -0.01 0.00
Purchase of Property, Plant & Equipment		 -0.00 - -0.01 -0.00 -0.01 - -0.01 - -0.01 -0.01 0.00
Purchase of Investments		 - - 0.00 - - - 0.00 - - - 0.00
Net Cash From Financing Activities		 -1.48 - 0.20 0.10 - 3.37 0.00 - - - 0.00
Net Cash From Continuing Financing Activities		 -1.48 - 0.20 0.10 - 3.37 0.00 - - - 0.00
Repurchase of Common Equity		 -1.48 - 0.00 - - - 0.00 - - - 0.00
Other Financing Activities, net		 - - 0.20 0.10 - 3.37 0.00 - - - 0.00

Annual Balance Sheets for Atossa Genetics

This table presents Atossa Genetics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 6.24 4.14 8.16 12 14 43 141 124 96 76 48
Total Current Assets		 4.29 3.25 7.90 12 14 43 141 118 92 74 46
Cash & Equivalents		 3.72 3.03 7.22 10 13 40 136 111 88 71 41
Restricted Cash		 0.28 0.06 0.06 0.11 0.11 0.11 0.11 0.11 0.11 0.11 0.11
Prepaid Expenses		 0.19 0.17 0.25 0.51 0.86 1.81 2.49 6.45 3.65 3.26 4.21
Plant, Property, & Equipment, net		 0.17 0.06 0.01 0.05 0.03 0.02 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 1.78 0.83 0.25 0.12 0.14 0.05 0.02 5.34 4.03 1.99 1.99
Long-Term Investments		 - - - - - - 0.00 4.70 1.71 - 0.00
Other Noncurrent Operating Assets		 0.08 0.19 0.18 0.02 0.07 0.04 - 0.64 2.32 1.99 1.99
Total Liabilities & Shareholders' Equity		 6.24 4.14 8.16 12 14 43 141 124 96 76 48
Total Liabilities		 2.50 1.05 1.23 2.92 1.33 16 3.13 5.57 5.24 4.97 8.26
Total Current Liabilities		 2.50 1.05 1.23 2.92 1.32 16 3.13 5.57 5.24 4.97 8.26
Accounts Payable		 0.81 0.25 0.33 0.35 0.29 1.59 1.72 2.97 0.81 0.68 4.29
Accrued Expenses		 0.46 0.02 0.09 0.18 0.08 0.09 0.20 1.06 0.97 0.92 1.31
Current Employee Benefit Liabilities		 1.16 0.77 0.78 2.35 0.90 0.96 1.18 1.53 1.65 1.86 1.56
Other Current Liabilities		 0.06 0.01 0.02 0.04 0.05 13 0.02 0.02 1.80 1.51 1.10
Total Noncurrent Liabilities		 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 3.74 3.10 6.94 8.81 13 27 138 118 91 71 39
Total Preferred & Common Equity		 3.74 3.10 6.94 8.81 13 27 138 118 91 71 39
Preferred Stock		 0.00 - 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 3.74 3.10 6.94 8.81 13 27 138 118 91 71 39
Common Stock		 55 60 72 83 107 138 267 274 279 285 287
Retained Earnings		 -51 -57 -65 -77 -94 -112 -129 -156 -186 -212 -247
Treasury Stock		 - - - - - - - 0.00 -1.48 -1.48 -1.48

Quarterly Balance Sheets for Atossa Genetics

This table presents Atossa Genetics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 102 91 86 79 71 65 58 38
Total Current Assets		 98 87 82 77 69 63 56 37
Cash & Equivalents		 94 84 80 75 65 58 52 32
Restricted Cash		 0.11 0.11 0.11 0.11 0.11 0.11 0.11 0.11
Prepaid Expenses		 3.47 2.99 2.08 2.24 3.52 4.55 3.72 4.84
Plant, Property, & Equipment, net		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 4.05 4.03 4.14 2.37 2.00 2.00 2.33 1.28
Long-Term Investments		 1.71 1.71 1.71 0.00 0.00 0.00 0.00 0.00
Other Noncurrent Operating Assets		 2.34 2.32 2.43 2.37 2.00 2.00 2.33 1.28
Total Liabilities & Shareholders' Equity		 102 91 86 79 71 65 58 38
Total Liabilities		 3.44 5.33 5.70 5.80 5.43 6.82 8.23 7.46
Total Current Liabilities		 3.44 5.33 5.70 5.80 5.43 6.82 8.23 7.46
Accounts Payable		 0.72 1.23 1.06 1.56 1.17 2.01 3.54 2.57
Accrued Expenses		 1.26 1.61 1.91 1.69 1.79 2.20 1.99 2.81
Current Employee Benefit Liabilities		 1.44 0.66 0.94 1.06 0.94 1.05 1.13 0.94
Other Current Liabilities		 0.02 1.83 1.79 1.48 1.53 1.56 1.58 1.14
Total Noncurrent Liabilities		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 98 86 80 74 65 58 50 30
Total Preferred & Common Equity		 98 86 80 74 65 58 50 30
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 98 86 80 74 65 58 50 30
Common Stock		 278 279 280 281 285 286 287 288
Retained Earnings		 -179 -192 -198 -205 -219 -227 -236 -256
Treasury Stock		 -1.48 -1.48 -1.48 -1.48 -1.48 -1.48 -1.48 -1.48

Annual Metrics And Ratios for Atossa Genetics

This table displays calculated financial ratios and metrics derived from Atossa Genetics' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 30,446,260.00 7,575,934.00 26,522,741.00 5,646,552.00 9,130,984.00 10,492,835.00 126,624,110.00 126,624,110.00 125,304,064.00 - 129,171,424.00
DEI Adjusted Shares Outstanding		 11,276.00 42,089.00 147,349.00 376,437.00 608,732.00 699,522.00 8,441,607.00 8,441,607.00 8,353,604.00 - 8,611,428.00
DEI Earnings Per Adjusted Shares Outstanding		 -1,397.69 -151.32 -72.55 -60.79 -28.32 -31.92 -2.44 -3.19 -3.60 - -4.04
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -95.62% -100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -6.80% 51.42% -31.79% -42.12% -51.28% -3.46% -15.79% -35.16% -23.66% 19.14% -33.44%
EBIT Growth		 -4.83% 50.08% -27.54% -40.41% -51.16% -3.41% -15.62% -35.05% -23.71% 19.15% -33.41%
NOPAT Growth		 -4.83% 37.54% 4.01% -49.48% -51.00% 15.40% -40.49% -34.94% -13.31% 11.97% -34.47%
Net Income Growth		 -7.52% 59.59% -27.54% -40.41% -51.16% -3.41% -15.58% -30.84% -11.62% 15.25% -36.33%
EPS Growth		 -7.52% 74.01% -27.54% 49.86% 63.09% 2.96% 0.00% 0.00% -14.29% 16.67% -36.33%
Operating Cash Flow Growth		 -32.19% 61.48% -22.69% -35.91% -1.86% -26.75% -42.37% -26.03% -0.87% -0.43% -41.52%
Free Cash Flow Firm Growth		 -51.45% 28.58% 14.29% -32.87% -114.00% 119.22% -1,141.23% 29.72% -2.07% 7.61% -25.30%
Invested Capital Growth		 -149.49% 105.68% -2,459.88% -404.97% 127.58% -2,788.07% 113.02% 39.15% -67.49% -61.55% -826.50%
Revenue Q/Q Growth		 -35.20% -100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 6.45% 0.61% 5.68% -0.86% -3.26% -37.70% 11.36% -13.56% -12.43% 18.92% -12.73%
EBIT Q/Q Growth		 6.29% 1.01% 6.13% -0.75% -3.23% -37.53% 11.37% -13.56% -12.47% 18.94% -12.73%
NOPAT Q/Q Growth		 6.28% 1.39% 4.58% -1.01% -3.04% -12.37% -3.03% -13.60% -2.87% 6.33% -13.04%
Net Income Q/Q Growth		 5.13% 27.68% 6.13% 0.00% 0.00% -37.53% 11.40% -10.94% -0.88% 5.23% -15.21%
EPS Q/Q Growth		 5.13% 25.77% 6.13% 0.00% 0.00% -53.91% 0.00% 0.00% 0.00% 9.09% -15.21%
Operating Cash Flow Q/Q Growth		 -9.70% 32.58% -5.21% -9.28% -2.99% -6.67% -1.43% -4.31% -5.27% -7.57% -13.28%
Free Cash Flow Firm Q/Q Growth		 -25.17% 5.68% -13.42% -16.12% -3.29% 127.03% -96.69% 10.00% -17.63% -10.77% -7.42%
Invested Capital Q/Q Growth		 -157.24% -98.54% -47.78% 30.39% 226.55% -2,003.88% 35.94% -64.51% -69.33% 123.68% 5.17%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 -7,431.91% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 -710,213.88% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 -725,746.19% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 -725,721.67% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 -896,491.64% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 123.53% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 99.97% 96.85% 87.39% 91.60% 93.60%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -7,024.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 -6,918.83% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 6,785.94% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -238.07% -186.26% -161.87% -144.88% -157.00% -88.42% -24.93% -21.05% -28.80% -31.39% -62.74%
Cash Return on Invested Capital (CROIC)		 0.00% -41,298.91% 0.00% 0.00% -3,062.40% 0.00% -1,750.93% -1,029.08% -1,362.39% -3,705.93% 0.00%
Operating Return on Assets (OROA)		 -141.70% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 -175.04% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -238.07% -186.26% -161.87% -144.88% -157.00% -88.42% -24.93% -21.05% -28.80% -31.39% -62.74%
Return on Equity Simple (ROE_SIMPLE)		 -421.20% -205.64% -117.06% -129.53% -131.04% -65.62% -14.92% -22.85% -33.06% -35.68% 0.00%
Net Operating Profit after Tax (NOPAT)		 -8.93 -5.58 -5.35 -8.00 -12 -10 -14 -19 -22 -19 -26
NOPAT Margin		 -508,022.33% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -105.18% -22.36% -53.46% -38.29% -44.47% -29.04% -7.09% -6.01% -7.89% -7.64% -15.58%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - -24.13% -27.05% -66.07%
Cost of Revenue to Revenue		 7,531.91% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 584,093.97% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 134,220.31% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 718,314.28% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -13 -6.37 -8.12 -11 -17 -18 -21 -28 -34 -28 -37
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -12 -6.07 -7.99 -11 -17 -18 -21 -28 -34 -28 -37
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 2.60 1.72 1.01 0.65 1.09 0.37 1.47 0.57 1.21 1.66 1.94
Price to Tangible Book Value (P/TBV)		 4.77 2.17 1.02 0.66 1.10 0.37 1.47 0.57 1.21 1.66 1.94
Price to Revenue (P/Rev)		 5,541.98 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 159.65 0.00 0.00 3.54 0.00 40.63 0.00 27.16 168.11 0.00
Enterprise Value to Revenue (EV/Rev)		 3,271.85 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.98 -1.03 -1.03 -1.13 -1.06 -1.30 -1.07 -0.98 -0.99 -0.99 -1.02
Leverage Ratio		 1.36 1.52 1.23 1.26 1.19 1.42 1.11 1.03 1.05 1.06 1.12
Compound Leverage Factor		 1.36 1.52 1.23 1.26 1.19 1.42 1.11 1.00 0.92 0.97 1.05
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -15.48 -20.73 -10.11 -10.32 -5.49 -3.89 38.30 5.79 9.83 10.36 -3.34
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 1.72 3.11 6.45 3.96 10.83 2.73 45.18 21.23 17.61 14.99 5.53
Quick Ratio		 1.49 2.89 5.89 3.56 9.51 2.52 43.63 19.92 16.89 14.31 5.00
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -8.18 -5.84 -5.01 -6.65 -14 2.74 -28 -20 -20 -19 -24
Operating Cash Flow to CapEx		 -10,672.96% -58,337.01% 0.00% -8,080.38% -119,717.27% -128,555.56% -183,022.22% -76,888.89% -149,578.57% -110,684.21% -129,400.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.20 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 1,829.66 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 -1,829.66 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -0.25 0.01 -0.33 -1.69 0.46 -12 1.63 2.26 0.74 0.28 -2.06
Invested Capital Turnover		 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -0.75 0.26 -0.35 -1.35 2.15 -13 14 0.64 -1.53 -0.45 -2.34
Enterprise Value (EV)		 5.75 2.26 -0.30 -4.73 1.64 -30 66 -49 20 48 35
Market Capitalization		 9.74 5.34 6.98 5.76 14 9.97 203 67 110 119 76
Book Value per Share		 $0.12 $0.82 $0.26 $1.56 $1.44 $2.59 $1.09 $0.93 $0.73 $0.57 $0.30
Tangible Book Value per Share		 $0.07 $0.65 $0.26 $1.54 $1.43 $2.59 $1.09 $0.93 $0.73 $0.57 $0.30
Total Capital		 3.74 3.10 6.94 8.81 13 27 138 118 91 71 39
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -3.99 -3.08 -7.27 -10 -13 -40 -136 -116 -90 -71 -41
Capital Expenditures (CapEx)		 0.13 0.01 0.00 0.11 0.01 0.01 0.01 0.03 0.01 0.02 0.02
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -2.20 -0.88 -0.60 -1.86 0.31 -13 1.63 1.63 -1.59 -1.70 -4.05
Debt-free Net Working Capital (DFNWC)		 1.79 2.21 6.67 8.63 13 27 138 113 87 69 37
Net Working Capital (NWC)		 1.79 2.21 6.67 8.63 13 27 138 113 87 69 37
Net Nonoperating Expense (NNE)		 6.83 0.79 2.77 3.40 5.15 7.60 6.24 7.58 8.13 6.17 8.77
Net Nonoperating Obligations (NNO)		 -3.99 -3.08 -7.27 -10 -13 -40 -137 -116 -90 -71 -41
Total Depreciation and Amortization (D&A)		 0.27 0.30 0.13 0.04 0.05 0.05 0.02 0.01 0.02 0.02 0.02
Debt-free, Cash-free Net Working Capital to Revenue		 -125,007.45% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 102,005.92% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 102,005.92% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($99.00) ($33.60) ($10.92) ($5.50) ($2.03) ($1.97) ($0.18) ($0.21) ($0.24) ($0.20) ($4.04)
Adjusted Weighted Average Basic Shares Outstanding		 215.69K 315.58K 2.65M 9.12M 9.13M 120.82M 126.62M 126.62M 126.08M 125.86M 8.61M
Adjusted Diluted Earnings per Share		 ($99.00) ($33.60) ($10.92) ($5.50) ($2.03) ($1.97) ($0.18) $0.00 ($0.24) ($0.20) ($4.04)
Adjusted Weighted Average Diluted Shares Outstanding		 215.69K 315.58K 2.65M 9.12M 9.13M 120.82M 126.62M 126.62M 126.08M 125.86M 8.61M
Adjusted Basic & Diluted Earnings per Share		 ($99.00) ($33.60) ($10.92) ($5.50) ($2.03) ($1.97) ($0.18) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 157.93K 189.82K 974.77K 4.16M 8.50M 11.31M 116.95M 126.62M 125.30M 129.17M 8.61M
Normalized Net Operating Profit after Tax (NOPAT)		 -8.93 -5.07 -5.03 -8.00 -12 -10 -14 -19 -22 -19 -26
Normalized NOPAT Margin		 -508,022.33% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 -725,721.67% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -4.90% 0.00% 0.00%

Quarterly Metrics And Ratios for Atossa Genetics

This table displays calculated financial ratios and metrics derived from Atossa Genetics' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 125,785,200.00 125,304,064.00 125,304,064.00 125,757,416.00 125,757,416.00 - 129,170,004.00 129,170,004.00 129,171,424.00 129,171,424.00 8,611,361.00
DEI Adjusted Shares Outstanding		 8,385,680.00 8,353,604.00 8,353,604.00 8,383,828.00 8,383,828.00 - 8,611,334.00 8,611,334.00 8,611,428.00 8,611,428.00 8,611,361.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.74 -0.93 -0.70 -0.72 -0.86 - -0.78 -0.98 -1.01 -1.27 -1.11
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 8.57% -46.64% 1.64% 8.98% 13.11% 54.28% -6.03% -27.34% -42.06% -58.40% -33.09%
EBIT Growth		 8.56% -46.78% 1.61% 8.96% 13.09% 54.30% -6.01% -27.32% -42.03% -58.37% -33.07%
NOPAT Growth		 8.98% -10.73% 1.66% 8.83% 14.50% 20.70% -6.22% -27.23% -44.89% -59.92% -33.13%
Net Income Growth		 22.24% -3.51% 6.42% 38.46% -16.07% 18.15% -14.29% -39.25% -20.22% -72.32% -42.74%
EPS Growth		 0.00% 0.00% 0.00% 37.50% -20.00% 33.33% -14.29% -40.00% -16.67% -72.32% -42.31%
Operating Cash Flow Growth		 28.23% -23.17% 33.10% -1.48% -22.33% -26.57% -26.84% -60.21% -26.42% -49.47% -60.78%
Free Cash Flow Firm Growth		 88.57% 24.51% 95.21% 97.29% 29.96% 4.85% -1,749.06% -5,810.20% -529.24% -24.46% -3.09%
Invested Capital Growth		 -62.38% -67.49% -100.46% -132.29% -149.79% -61.55% 557.14% 77.03% -81.42% -826.50% -1,497.92%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 4.09% -59.55% 41.41% -1.53% 8.44% 33.50% -3.52% -21.93% -2.14% -22.87% 13.02%
EBIT Q/Q Growth		 4.09% -59.67% 41.44% -1.51% 8.44% 33.48% -3.52% -21.91% -2.14% -22.86% 13.02%
NOPAT Q/Q Growth		 4.17% -20.76% 22.60% -1.79% 10.13% -12.00% -3.68% -21.93% -2.33% -23.62% 13.69%
Net Income Q/Q Growth		 36.63% -24.48% 24.19% -2.91% -19.52% 12.21% -5.85% -25.38% -3.19% -25.83% 12.33%
EPS Q/Q Growth		 37.50% -20.00% 16.67% 0.00% -20.00% 33.33% -5.85% -40.00% 0.00% -25.83% 12.60%
Operating Cash Flow Q/Q Growth		 13.03% -43.47% 15.67% 3.55% -4.83% -48.44% 15.49% -21.82% 17.28% -75.50% 9.09%
Free Cash Flow Firm Q/Q Growth		 72.33% -283.20% 94.00% 57.32% -613.88% -420.61% -16.56% -36.43% 24.00% -2.97% 3.45%
Invested Capital Q/Q Growth		 -34.55% -69.33% -102.85% -5,538.10% -0.93% 123.68% -66.08% -383.33% -697.06% 5.17% 34.73%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 83.02% 64.72% 83.78% 84.93% 110.87% 115.93% 90.32% 92.89% 93.85% 96.12% 96.88%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -26.86% -28.80% -29.84% -28.00% -31.30% -31.39% -34.87% -41.66% -48.89% -62.74% -78.58%
Cash Return on Invested Capital (CROIC)		 -395.79% -1,362.39% 0.00% 0.00% 0.00% -3,705.93% -20,578.65% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -26.86% -28.80% -29.84% -28.00% -31.30% -31.39% -34.87% -41.66% -48.89% -62.74% -78.58%
Return on Equity Simple (ROE_SIMPLE)		 -30.36% 0.00% -34.62% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -5.23 -6.31 -4.89 -4.97 -4.47 -5.01 -5.19 -6.33 -6.48 -8.01 -6.91
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -0.94% -1.40% -1.02% -1.18% -3.23% -1.66% -2.02% -3.01% -3.49% -5.21% -5.52%
Return On Investment Capital (ROIC_SIMPLE)		 - -6.94% -5.70% -6.20% -6.07% -7.00% -7.94% -10.97% -13.01% -20.34% -22.66%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -7.50 -12 -7.02 -7.12 -6.52 -5.48 -7.44 -9.07 -9.26 -11 -9.90
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -7.50 -12 -7.01 -7.12 -6.52 -5.47 -7.43 -9.06 -9.26 -11 -9.89
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.94 1.21 2.63 1.87 2.59 1.66 1.33 1.86 2.25 1.94 1.49
Price to Tangible Book Value (P/TBV)		 0.94 1.21 2.63 1.87 2.59 1.66 1.33 1.86 2.25 1.94 1.49
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 27.16 0.00 0.00 0.00 168.11 225.96 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.96 -0.99 -0.98 -0.99 -0.99 -0.99 -1.00 -1.01 -1.03 -1.02 -1.01
Leverage Ratio		 1.03 1.05 1.04 1.05 1.05 1.06 1.07 1.09 1.11 1.12 1.13
Compound Leverage Factor		 0.85 0.68 0.87 0.89 1.17 1.23 0.97 1.01 1.05 1.08 1.10
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 14.55 10.60 23.27 13.32 16.98 11.32 6.02 5.08 2.94 -1.56 -5.74
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 28.35 17.61 16.34 14.35 13.30 14.99 12.67 9.17 6.77 5.53 4.92
Quick Ratio		 27.30 16.89 15.76 13.96 12.90 14.31 12.00 8.48 6.30 5.00 4.25
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -1.25 -4.78 -0.29 -0.12 -0.87 -4.55 -5.31 -7.24 -5.50 -5.67 -5.47
Operating Cash Flow to CapEx		 -388,300.00% 0.00% -78,300.00% -151,033.33% -47,500.00% 0.00% -66,211.11% 0.00% -85,785.71% -150,557.14% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 2.40 0.74 -0.02 -1.18 -1.20 0.28 0.10 -0.27 -2.17 -2.06 -1.34
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -3.98 -1.53 -4.60 -4.85 -3.60 -0.45 0.12 0.91 -0.97 -2.34 -1.44
Enterprise Value (EV)		 -3.21 20 140 68 116 48 22 49 60 35 13
Market Capitalization		 93 110 226 150 191 119 87 107 112 76 45
Book Value per Share		 $0.78 $0.73 $0.68 $0.64 $0.59 $0.57 $0.51 $0.45 $0.39 $0.30 $3.54
Tangible Book Value per Share		 $0.78 $0.73 $0.68 $0.64 $0.59 $0.57 $0.51 $0.45 $0.39 $0.30 $3.54
Total Capital		 98 91 86 80 74 71 65 58 50 39 30
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -96 -90 -86 -81 -75 -71 -65 -58 -52 -41 -32
Capital Expenditures (CapEx)		 0.00 0.00 0.01 0.00 0.01 0.00 0.01 0.00 0.01 0.01 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.06 -1.59 -2.34 -3.61 -3.56 -1.70 -1.91 -2.27 -4.50 -4.05 -2.62
Debt-free Net Working Capital (DFNWC)		 94 87 82 76 71 69 63 56 47 37 29
Net Working Capital (NWC)		 94 87 82 76 71 69 63 56 47 37 29
Net Nonoperating Expense (NNE)		 1.00 1.44 0.99 1.08 2.76 1.34 1.53 2.10 2.22 2.93 2.68
Net Nonoperating Obligations (NNO)		 -96 -90 -86 -81 -75 -71 -65 -58 -52 -41 -32
Total Depreciation and Amortization (D&A)		 0.00 0.01 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.05) ($0.06) ($0.05) ($0.05) ($0.06) ($0.04) ($0.75) ($0.07) ($0.07) ($19.05) ($1.11)
Adjusted Weighted Average Basic Shares Outstanding		 125.79M 126.08M 125.32M 125.73M 125.77M 125.86M 8.61M 129.17M 129.17M 574.09K 8.62M
Adjusted Diluted Earnings per Share		 $0.00 ($0.06) ($0.05) ($0.05) ($0.06) ($0.04) ($0.75) ($0.07) ($0.07) ($19.05) ($1.11)
Adjusted Weighted Average Diluted Shares Outstanding		 125.30M 126.08M 125.32M 125.73M 125.77M 125.86M 8.61M 129.17M 129.17M 574.09K 8.62M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 ($19.05) $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 125.30M 125.30M 125.76M 125.76M 125.80M 129.17M 8.61M 129.17M 129.17M 574.09K 8.61M
Normalized Net Operating Profit after Tax (NOPAT)		 -5.23 -6.31 -4.89 -4.97 -4.47 -5.01 -5.19 -6.33 -6.48 -8.01 -6.91
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -4.94% -4.90% -4.97% -5.69% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Atossa Genetics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Atossa Genetics' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Atossa Genetics' net income appears to be on an upward trend, with a most recent value of -$34.77 million in 2025, rising from -$15.76 million in 2015. The previous period was -$25.50 million in 2024. Find out what analysts predict for Atossa Genetics in the coming months.

Atossa Genetics' total operating income in 2025 was -$37.14 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $37.14 million

Over the last 10 years, Atossa Genetics' total revenue changed from $1.76 thousand in 2015 to $0.00 in 2025, a change of -100.0%.

Atossa Genetics' total liabilities were at $8.26 million at the end of 2025, a 66.2% increase from 2024, and a 230.0% increase since 2015.

In the past 10 years, Atossa Genetics' cash and equivalents has ranged from $3.03 million in 2016 to $136.38 million in 2021, and is currently $41.30 million as of their latest financial filing in 2025.

Over the last 10 years, Atossa Genetics' book value per share changed from 0.12 in 2015 to 0.30 in 2025, a change of 147.9%.


Related Companies

Financial statements for NASDAQ:ATOS last updated on 7/16/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
What Saudi Arabia just did to the dollar changes everything
In June 2024, a 50-year arrangement tying Saudi oil to the U.S. dollar quietly expired. Garrett Goggin, CFA, C...
Golden Portfolio | Sponsoredtc pixel
The only metrics you should watch as a day trader.
Day traders and swing traders don't need the same metrics - and using the wrong ones costs you edge. After 40 ...
The TradingPub | Sponsoredtc pixel
Trump’s $250 Bill – See Immediately
Former Goldman Sachs VP Dr. David Eifrig is warning that July 28 could trigger the biggest wealth reset in mod...
Stansberry Research | Sponsoredtc pixel
BlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely, LLC | Sponsoredtc pixel
When I found Rolls-Royce under $2, most people thought I was crazy
In 2022, Karim Rahemtulla recommended Rolls-Royce when it traded under $2. The stock climbed more than 1,100% ...
Monument Traders Alliance | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
AI investors should get ready for a BIG surprise
Wall Street insider Jason Bodner - who called Nvidia at $4.50 - says today's most popular AI stocks are about ...
Brownstone Research | Sponsoredtc pixel
Elon just confirmed my prediction
Elon Musk has officially confirmed a major new financial venture - and over 1 billion dollars is already flowi...
InvestorPlace | Sponsoredtc pixel